Unicycive Therapeutics UNCY
NASDAQ UNCY
$3.78 +0.12 (+3.28%)
At close: Nov 11, 2026 · 4:00 PM EST

Unicycive Therapeutics (UNCY) EBITDA Margin (2022 - 2024)

Updated

Unicycive Therapeutics (UNCY) reported EBITDA Margin of -3076.30% for FY2023, down 1223.09 percentage points from -1853.21% in FY2022.

Analysis

Unicycive Therapeutics (UNCY) EBITDA Margin (2022 - 2024) Analysis & Trends

  • According to Business Quant data, EBITDA Margin came in at -1853.21% in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Unicycive Therapeutics 101.95 Mn -98.02 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 -1,362.22%
Mar 31, 2023 -622.22%
Sep 30, 2022 -583.91%
API Access

Unicycive Therapeutics EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=UNCY&period=max&api_key=YOUR_API_KEY